Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study

Isabelle M. Dudley, Ceren Sunguc, Emma J. Heymer, David L. Winter, Jop C. Teepen, Fabiën N. Belle, Edit Bárdi, Francesca Bagnasco, Thorgerdur Gudmundsdottir, Roderick Skinner, Gisela Michel, Julianne Byrne, Hilde Øfstaas, Momcilo Jankovic, Maja Česen Mazić, Luzius Mader, Jaqueline Loonen, Stanislaw Garwicz, Thomas Wiebe, Daniela AlessiRodrigue S. Allodji, Nadia Haddy, Desiree Grabow, Peter Kaatsch, Melanie Kaiser, Milena M. Maule, Zsuzsanna Jakab, Maria Winther Gunnes, Monica Terenziani, Lorna Zadravec Zaletel, Claudia E. Kuehni, Riccardo Haupt, Florent de Vathaire, Leontien C. Kremer, Päivi M. Lähteenmäki, Jeanette F. Winther, Lars Hjorth, Michael M. Hawkins, Raoul C. Reulen

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

Samenvatting

Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. Results: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). Conclusions: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.

Originele taal-2Engels
TijdschriftCancer
DOI's
StatusGeaccepteerd/In druk - 2022

Vingerafdruk

Duik in de onderzoeksthema's van 'Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study'. Samen vormen ze een unieke vingerafdruk.

Citeer dit